OncoTherapy Science Competitors and Similar CompaniesClear all
OncoTherapy Science's competitors and similar companies include Immutep, Bexion Pharmaceuticals, Acrivon and Disco Pharmaceuticals.
 OncoTherapy Science OncoTherapy Science is a company engaged in research and development of cancer therapeutics. |  Immutep Immutep (formerly Prima BioMed) is a biotechnology company focused on developing autoimmune and cancer immunotherapy treatment. |  Bexion Pharmaceuticals Bexion Pharmaceuticals is a company committed to the discovery, clinical development, and acquisition of oncology treatments. |  Acrivon Acrivon (also known as Acrivon Therapeutics) is a clinical-stage oncology company that leverages a precision medicine platform called Acrivon Predictive Precision Proteomics (AP3) for the development of a drug pipeline. |  Disco Pharmaceuticals Disco Pharmaceuticals is a biotechnology company that specializes in cancer treatment solutions. | |
Founding Date | Founding Date 2001 | Founding Date 2001 | Founding Date 2006 | Founding Date 2018 | Founding Date 2022 |
Type | Type Public | Type Public | Type Private | Type Public | Type Private |
Tags | |||||
Locations | Locations Kawasaki, JP HQ | Locations Sydney, AU HQ Sydney, AU The Rocks, AU Orsay, FR Berlin, DE Leipzig, DE | Locations Covington, US HQ | Locations Watertown, US HQ Lund, SE | Locations Cologne, DE HQ |
Employees | Employees 54 | Employees 2427% decrease | Employees 274% increase | Employees 415% increase | Employees 288% increase |
Valuation ($) | Valuation ($) 56.9 m | Valuation ($) 282.4 m | Valuation ($) N/A | Valuation ($) 256.1 m | Valuation ($) N/A |
Financial | |||||
Revenue (est.) | Revenue (est.) ¥808.5m (FY, 2026) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) N/A |
Cost of goods | Cost of goods ¥794.6m (FY, 2026) | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A |
Gross profit | Gross profit ¥14m (FY, 2026) | Gross profit $5m (FY, 2025) | Gross profit N/A | Gross profit N/A | Gross profit N/A |
Net income | Net income (¥910.6m) (FY, 2026) | Net income ($61.4m) (FY, 2025) | Net income N/A | Net income ($77.9m) (FY, 2025) | Net income N/A |
Funding | |||||
Latest funding round | Latest funding round N/A | Latest funding round N/A | Latest funding round $ 16.6m (about 7 years ago) | Latest funding round N/A | Latest funding round $ 21.7m (over 2 years ago) |
Total funding raised | Total funding raised N/A | Total funding raised N/A | Total funding raised $ 16.6m | Total funding raised N/A | Total funding raised $ 21.7m |
For sources of this data, please see the company profile
View Company Profiles
Immutep
HQ
Sydney, AU
Employees
24↓ 27% decrease
Immutep (formerly Prima BioMed) is a biotechnology company focused on developing autoimmune and cancer immunotherapy treatment.
View companyBexion Pharmaceuticals
HQ
Covington, US
Employees
27↑ 4% increase
Bexion Pharmaceuticals is a company committed to the discovery, clinical development, and acquisition of oncology treatments.
View companyAcrivon
HQ
Watertown, US
Employees
41↑ 5% increase
Acrivon (also known as Acrivon Therapeutics) is a clinical-stage oncology company that leverages a precision medicine platform called Acrivon Predictive Precision Proteomics (AP3) for the development of a drug pipeline.
View companyDisco Pharmaceuticals
HQ
Cologne, DE
Employees
28↑ 8% increase
Disco Pharmaceuticals is a biotechnology company that specializes in cancer treatment solutions.
View company